Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

If you have a question about this talk, please contact Melanie Witt.

Professor Steven Gill pioneered the original work using Glial cell line-Derived Neurotrophic Factor (GDNF) in people with Parkinson’s. Since the initial pilot study, he has designed a new delivery system to enable this key growth factor to be delivered optimally, not only in terms of safety and efficacy, but also in a way which can be administered to patients practically and accurately.

Professor Gill’s Functional Neurosurgery Research Group has extensive pre-clinical and clinical Convection-enhanced delivery (CED) research experience and has successfully completed a number of studies which have led directly to clinical trials. This group has unique and world-leading  CED  catheter technology which is currently being used to treat patients with a range of neurological disorders including adults and children with malignant brain tumours and Parkinson’s Disease.

Topics: Parkinson’s disease—Surgery, Parkinson’s disease

Organisers: Melanie Witt (University of Oxford, Department of Earth Sciences, Department of Physiology Anatomy and Genetics)

Contact email:

Audience: Members of the University only

Booking: Not required

DPAG Head of Department Seminar Series